Study of Tremelimumab in Patients with Advanced Solid Tumors

Trial Identifier: D4884C00001
Sponsor: AstraZeneca
NCTID:: NCT02527434
Start Date: November 2015
Primary Completion Date: February 2018
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Dutch Translation
Dutch Translation
French Translation
German Translation
Korean Translation
Polish Translation

Trial Locations

Country Location
BE Brussels, BE, 1090
BE Charleroi, BE, 6000
BE Wilrijk, BE, 2610
KR Daejeon, KR, 35015
KR Seoul, KR, 03722
KR Seoul, KR, 03080
KR Seoul, KR, 135-710
NL Groningen, NL, 9713 GZ
NL UTRECHT, NL, 3584 CX
PL Gdańsk, PL, 80-214
PL Łódź, PL, 93-513
US, CA San Francisco, CA, US, 94158
US, TN Memphis, TN, US, 38120
US, TX Houston, TX, US, 77030